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Although no special recommendations exist, clearly patients with cystic fibrosis (CF) can benefit from immunisation. We reviewed the
literature regarding vaccination in CF and other chronic diseases. CF subjects should follow national immunisation programmes without
delay to obtain optimal vaccination coverage. Indeed they may escape normal programmes due to frequent hospital admissions and school
absenteeism and may be more at risk to get ‘‘vaccine-controlled’’ diseases at any age. There is no uniform European immunisation schedule
for basic infant and childhood vaccines or for vaccines against hepatitis A (HAV) and B (HBV), varicella (VZ) and booster vaccinations.
HAV and HBV vaccination is appropriate in CF as recommended in general for patients with chronic liver disease (CLD). Varicella (VZ)
vaccination is not recommended in all European countries. There are no recent data about possible worsening of pulmonary status following
VZ in CF, but it is known to cause pulmonary damage in non-CF adults and to be potentially fatal post transplantation and during steroid
treatment. Therefore it is recommended at least for seronegative adolescents and transplant candidates. Influenza vaccine is recommended
annually for CF patients aged 6 months. Pneumococcal vaccine is generally indicated for CF patients. RSV infection might play a role in
the initial Pseudomonas colonization and the decline in pulmonary function. However no RSV vaccine is available at present. There are no
recommendations for palivizumab in CF as an alternative but expensive prophylaxis. Anti-bacterial vaccinations protecting directly against
Pseudomonas aeruginosa colonisation are promising for the future, potential candidates are currently being assessed in phase III clinical
trials. More studies are needed to complete recommendations especially for CF adults and transplant candidates.
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Forty years ago cystic fibrosis (CF) patients seldom
survived beyond infancy and vaccination was far from being
a priority. Although the introduction of better diagnostic
techniques and refinements of therapeutic strategies has
increased the median age of survival beyond 30 years [1,2],
little attention has been paid to the contribution of
vaccination to the current management of CF patients. A
standard protocol on anti-viral and anti-bacterial vaccination
could improve health care in CF, but until now there have
been no specific recommendations for immunisation of CF
children and adults as there are for other diseases [3–5].
Young CF children may easily escape normal national
immunisation programmes, being more often absent from
school and admitted to the hospital for treatment by
specialists. Indeed, all children with a chronic disease run
a higher risk of incomplete and delayed immunisation than
healthy children [6]. Secondly, knowing that the adult
population is greatly expanding, older children and adults
with CF even despite being vaccinated correctly in infancy
and childhood, might become susceptible to preventable
diseases such as pertussis because for some diseases vaccine
induced immunity wanes over time [7–11]. Little is known
as to what extent, these diseases could cause pulmonary
deterioration in CF. This must be a matter of concern in the
adult care setting, which might be less involved in routine
vaccination than paediatrics. Moreover, vaccination cover-
age has decreased due to ill-founded worries about vaccine
safety [12] and the fact that most people no longer realise
the severity of vaccine-preventable diseases because of the
success of earlier immunisation programmes. The average
coverage for ‘‘classic’’ vaccinations such as diphtheria,
tetanus, pertussis and poliomyelitis in Europe is insufficient,
with many countries attaining only low levels. Therefore
vaccine-preventable diseases are not yet sufficiently con-
trolled in Europe [13,14].
Current national vaccination schedules in the European
countries differ widely, for instance for hepatitis A and B,
and some booster vaccinations and we are far from a
uniform European immunisation system [13,14]. This
applies to both to different single vaccines as well as
combinations. There is also considerable variation in
legislation, the implementation systems and vaccination
coverage in general. In some countries, vaccinations are
centralised by the government, while other countries use
decentralised private vaccination systems paid for by
insurance companies [14]. Therefore data on vaccination
coverage of CF patients are to our knowledge unavailable.
For this reason also, data on the prevalence and
complications of vaccine-preventable diseases in CF are
lacking.
A number of points need to be emphasised. First of all, it
is important to underline that CF itself is not a contra-
indication to routine immunisation and that optimal cover-
age for routine vaccines against tetanus, diphtheria, pertus-sis, poliomyelitis, measles, rubella, and mumps must be
obtained [2]. Moreover, CF patients are candidates for extra
vaccinations such as influenza, hepatitis, varicella, RSV
[2,3,15] and perhaps most importantly Pseudomonas
aeruginosa [16]. Some of these infections can be a
contraindication to referral for transplantation. Since more
than 90% of the mortality in CF is pulmonary, early
immunisation are an important tool to prevent transplanted
subjects being vulnerable to life-threatening vaccine-pre-
ventable infectious agents. Finally, CF patients have not
been systematically studied to determine whether they make
a normal response to all vaccines and the possibility of
vaccine-failure is still an unanswered issue. Based on a
review of the literature, we have attempted to establish
recommendations for CF patients, independent of the
countries’ national schedule and system. This document
summarises information gathered by the authors, who are
involved in immunisation programmes, in paediatric and
adult CF care and in CF transplantation teams.2. General recommendations
Although national vaccination schedules differ widely in
the European countries, the obvious place to start is from the
national recommendations and strategies of immunisation,
and to apply them to all CF patients to obtain optimal
coverage (Table 1). In CF patients, in children as well as in
adults wheeze or cough are no reasons to withhold or delay
vaccination, and the general practitioner can play a
particularly important role in vaccine coverage [2]. New
recommendations for conjugate pneumococcal and menin-
gococcal C vaccines as well as for pertussis boosters in
adolescent and adults should be implemented. With regard
to BCG, national guidelines should be followed, although as
with many recommendations, there are gaps in our knowl-
edge as to how the CF patient will respond to immunisation.
Although tuberculosis (TB) is rare in CF patients, there are
obvious diagnostic difficulties, and since occult TB could be
reactivated after transplantation, immunisation in accord
with established local practice seems logical.
Vaccines should be withheld only under exceptional
circumstances such as any recent or present treatment with
oral prednisolone: doses of 2mg/kg/day or above may
compromise the efficacy of any vaccines and may be a
danger in live vaccines of contracting the disease [3].
Inhaled steroids, other in very high doses, are not a
contraindications to vaccine administration.
In adolescence and when transplantation is considered, a
vaccination check-up should be done, and any gaps in the
vaccinations should be remedied (Table 2). There are no
data on whether Haemophilus influenzae type b and
pneumococcal vaccine immune response can be depressed
in CF and that vaccination should be repeated. Specific
antibody monitoring is helpful in determining the need for
individual boosters.
Table 1
























X X X X X X
Diphtheria, tetanus,
pertussis adult
boosters recommended in some
countries at 6 years, adolescents, adults
Haemophilus influenzae
type b
X X X X
Hepatitis B X X X X (xxx) (xxx) not in countries with low prevalence
Hepatitis A (xx) recommended in selected EU regions
Measles, mumps, rubella X (X) (X) (X) booster recommended since 1995, age variable
Varicella X (xx) recommended in some countries 2 doses >13 years
Meningococcal C in some regions with increased prevalence, age
cohort variable
Pneumococcal conj recommended in some countries
Influenza virus recommended in patients at risk
BCG (TB) X recommended at birth+booster at 6/12 years in
some countries
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mised hosts after lung or liver transplantation are listed in
Table 3. It is clear that live-attenuated vaccines such as
varicella vaccine, oral poliomyelitis vaccine, measles-
mumps-rubella and BCG cannot be administered in
immunosuppressed subjects and that they should be
scheduled before transplantation [3].
Depending on the country, national recommendations
alone may be insufficient for CF patients. Vaccinations not
recommended for healthy children in general or differently
implemented in national vaccination schedules will be
discussed separately in relation to CF in general and to
CF lung transplant candidates.Table 3
Immunisation in immunosuppressed patients (including high dosis steroid
treatment)3. Hepatitis A and B
Infection with the hepatitis A virus (HAV) results in a
self-limited disease, which does not become chronic. When
acquired in adulthood, more serious morbidity occurs and





1. booster poliomyelitis (inactivated)-diphtheria-tetanus-pertussis
2. vaccination against hepatitis A and B
3. antibody level against varicella-measles-mumps-rubella-pneumococci
and if insufficientYcomplete vaccination
To consider
pneumococcal/Haemophilus influenzae b/meningococcal C
vaccinationalised countries, up to 50% of adults have detectable anti-
HAV antibodies, although overall seropositivity rates due to
natural infection are declining. A few reports have been
published showing a higher case-fatality rate of hepatitis A
infection in chronic liver disease patients (CLD) compared
to non-CLD patients.
In a retrospective study from the Centers for Disease
Control and Prevention (CDC), the hepatitis A case-
fatality rate is 4.6% in patients with pre-existing CLD,
approximately 23-fold higher than for patients without
pre-existing liver disease [17]. Four cases of fulminate
hepatic failure and death secondary to acute hepatitis A
infection in patients with intravenous drug abuse and
alcoholic liver disease have been reported by Akriviadis
[18]. A large survey conducted by Williams [19] has
shown that HAV superinfection of patients with CLDVaccine Authorised Remarks
Poliomyelitis X only inactivated
intramuscular
vaccine authorised
Diphtheria, tetanus, pertussis X
Diphtheria, tetanus, pertussis adult X
Haemophilus influenzae type b X response may be decreased
Hepatitis B X
Hepatitis A X
Measles, mumps, rubella NO live attenuated vaccine
Varicella NO live attenuated vaccine
Meningococcal C X response may be decreased
Pneumococcal 23-valent X response may be decreased
Pneumococcal conjugated X response may be decreased
Influenza virus X response may be decreased
BCG (TB) NO live attenuated vaccine
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CLD patients.
Two vaccine studies have investigated the safety and
immunogenicity of inactivated hepatitis A vaccine in
patients with CLD [20–22]. It can be concluded from these
studies that the vaccine is safe and well tolerated, with lower
but satisfactory geometric mean titres compared to healthy
individuals.
Hepatitis B virus (HBV) infection, in contrast to the
rather benign character of HAV, can result in a chronic
carrier state in 5–10% of adult patients, and in >30% of
infected children. It is estimated that there are approximately
367 million chronic carriers of hepatitis B virus worldwide.
About 25% of these carriers will develop serious chronic
liver disease, including chronic hepatitis, liver cirrhosis and
primary hepatocellular carcinoma. Limited data are avail-
able on the outcome of hepatitis B infection in patients with
CLD [23]. Generally, hepatitis B vaccination is imple-
mented in national schedules except in some countries with
a low prevalence. WHO recommends the inclusion of
hepatitis B vaccination into all national immunisation
programmes [14,24,25].
CF patients are predisposed to liver disease because of
lack of a functional CF transmembrane conductance
regulator protein on the biliary epithelium. Although
longitudinal data describing and quantifying the liver
abnormalities [26] are still not available in the literature,
chronic liver disease accounts for virtually all non-pulmo-
nary causes of mortality in CF patients. Therefore, along
with lung disease and nutritional status, liver disease is an
important predictor of the outcome of CF [27]. Cross
sectional studies have described a prevalence of CF liver
disease of 1.4–7% when diagnosed as hepatosplenomegaly
on clinical examination. However a far greater prevalence is
suggested by abnormal liver ultrasonography and biochem-
ical tests [26,28], and in a recent study over 4 years Ling
[26] found some evidence of liver abnormality in 92% of
children under the age of 14 years. With increasing survival
of CF patients, some authors predict an increasing predis-
position to cancer. In a study including more than 38,000
North American and European CF patients, an excess of
digestive cancers including liver cancer was shown. Many
of these patients were only in their third decade at the time
of their cancer diagnosis [29].
Inactivated hepatitis A vaccine and recombinant hepatitis
B vaccine have been extensively studied and shown to be
safe and efficacious in preventing infection [30,31]. In
recent years, several studies have investigated the outcome
of HAV or HBV infection of patients with chronic liver
disease (CLD) and discussed the rationale of vaccinating
these patients against HAV and HBV, including in countries
with a low risk of hepatitis where these immunisations are
not included in the routine national programme [5,20–22].
Up to now CF has not been specifically considered. Data on
hepatitis A and B prevalence or vaccination coverage of CF
patients are lacking. As some evidence of liver abnormalitycan be found in up to 92% of CF patients, CF patients are
expected to run a higher probability of fatal hepatitis A and
B infection when exposed to these viruses. Most CF patients
do not have identifiable risk factors. For this reason, CF
patients should be considered as a target group for
vaccination. An appropriate time to vaccinate them is the
time point of diagnosis of CLD [22] or preferably at the time
of CF diagnosis. This is in line with reports from the World
Health Organisation and from CDC, recommending vacci-
nation for persons with CLD caused by viral hepatitis or
other aetiologies [24,32].
With the availability of a combined hepatitis A and B
vaccine, which has shown to be safe, well tolerated and
highly immunogenic, it is worth considering using this
combined vaccine in CF patients. It offers dual protection in
a simple schedule (0, 1, 6 months) [33].4. Measles-mumps-rubella
The symptoms of measles include cough, coryza, general
irritation of the respiratory tract with complications of the
ears (otitis) and the lungs (bronchopneumonia). These
particular symptoms and complications may add an extra
burden on the respiratory system of CF patients. Although
data on the epidemiology of vaccine-preventable diseases in
Europe are incomplete, it is clear that measles is not yet
controlled in most European countries [14,34]. An impor-
tant aspect is the unsuccessful achievement of high
population vaccine coverage in some European regions,
due to ill-founded public fears, resulting in regional measles
outbreaks [14,34]. The epidemiology of measles morbidity
has changed in the last 3 decades and hence the extent of
exposure to the wild virus in immunised individuals is
unknown. It has, however been suggested that about 1% of
immunised persons per year may lose protection [35].
Measles vaccine combined with rubella and mumps
(MMR) vaccines have been included in all basic vaccination
schedules since the early eighties. The age recommended for
primary immunisation is 12–15 months (Table 1). Anti-
bodies develop in approximately 95% of children immu-
nised at 12 months and 98% of those immunised at 15
months of age. Recommendations for a booster at 4, 6 or 12
years have been implemented in the mid-nineties after
school-based outbreaks, to prolong immunity and possibly
eradicate measles [13,36,37]. More than 99% of individuals
who receive 2 doses of measles vaccine (separated by at
least 1 month) after the age of 1 year, develop serologic
evidence of measles immunity [37]. Protection conferred by
immunisation is long lasting in most people. A small
percentage may lose protection after several years. In
countries with high immunisation coverage, population
immunity and elimination of the virus ensure continued
protection.
A specific recommendation should be made that CF
patients ensure they are immune to measles. In most
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one dose of measles vaccine in the early eighties, before the
later recommendations for the booster at school age, so that
a cohort of young CF adults are currently incompletely
immunised. Measles vaccination is recommended to all CF
adults who do not have a valid documentation of a history of
measles disease or a documented correct complete vacci-
nation administered after the age of 12 months, consisting of
2 doses separated by at least 4 weeks.5. Varicella
Varicella-zoster (VZ) virus predominantly affects young
children and is generally perceived as benign. However in a
recent 13-month survey of severe complications of VZ in
hospitalised children less than 16 years of age, 78%
complications were seen in children younger than 4 years.
Bacteraemia, pneumonia, encephalitis and ataxia were most
frequently reported [38–41]. After adolescence the risk for
severe pulmonary complications rises, and varicella may be
particularly harmful for CF adults, although recent data on
specific effects in CF are almost completely lacking
[38,42,43]. In adults, pneumonia is the most serious
complication in terms of morbidity and mortality and may
be life-threatening [44–47]. An upward shift in the age
distribution of VZ was described 10 years ago in the UK as
well as in the USA before the implementation of the
vaccination, resulting in an increased risk of infection in
pregnant women, health care workers and vulnerable
chronic patients [48]. Moreover, VZ is a serious, life-
threatening disease in immunocompromised hosts, such as
patients on steroids and transplanted subjects [15,49,50].
Varicella vaccine has been introduced in the universal
vaccination schedule of the USA in the nineties [51] and
recently in some European countries, implementing one
dose of VZ vaccine for the immunisation of all immuno-
competent children at age 12–18 months. Catch-up
immunisation of subjects aged 19 months to 13 years is
recommended in those who do not have a reliable history of
chickenpox. The vaccine has been found to be safe and
immunogenic in adults and elderly [52]. To control VZ
disease, a coverage rate of over 85% of the population is
required, which may be difficult to obtain in Europe [40,53].
Experience concerning the effects of inefficient vaccination
coverage of the population is limited in VZ and the time
needed to obtain the target level of 85% coverage cannot be
predicted. As immunisation will be gradually introduced in
vaccination schedules, a further switch of morbidity to older
ages is at risk of occurring. In an American report [54], VZ
vaccine is stated to give protection against disease 7 years
after vaccination, in a population with 20% vaccine cover-
age, and has not lead to the earlier described age-shift of the
disease. Re-exposure to the wild type virus could have
contributed to maintain VZ antibody responses and long-
term protection in those vaccinated people living in apopulation with a low vaccine coverage. When coverage
rises, re-exposure of vaccines with of waning immunity to
VZ will decrease. For the moment there are no recommen-
dations for the introduction of booster vaccinations to
prevent people from becoming more susceptible to VZ in
later life [52].
CF patients should be considered as a target group for
VZ vaccination for multiple reasons: VZ infection can cause
pulmonary deterioration and a proportion of the CF
population will receive steroids or be immunosuppressed
after transplantation [43,48–50]. The most appropriate time
for children to be vaccinated, is preferably, as soon as the
diagnosis of CF is made (1 dose at age 1–13 years).
Adolescents past their 13th birthday and young adults,
without a history of VZ, should be immunised by
administration of 2 doses of vaccine 4–8 weeks apart.
Longer intervals between doses do not necessitate a third
dose [55]. All patients who do not have a valid documenta-
tion of a history of VZ disease or a documented correct
complete vaccination should at least be vaccinated before
being put on the transplant waiting list.6. Influenza
Influenza virus infection is a cause of substantial
morbidity and mortality, particularly in vulnerable popula-
tions. Recent data report that infants with CF acquiring
respiratory virus infection show lung function deterioration,
which may persist for months after the acute illness [56].
Although recent studies on influenza virus infection as a
trigger for the onset of bacterial pulmonary infections in CF
children are lacking, the role of influenza was highlighted in
several older studies [57–59]. Influenza significantly
increases the incidence of hospitalisation and of respiratory
illness in children with CF. Influenza virus infection is
shown to be one of the main mediators of the onset of
chronic P. aeruginosa infection in CF [57]. Even though
reports have documented that school-age patients with CF
are not more susceptible to viral infections than their healthy
siblings [60], recent studies have identified healthy non-CF
children as a risk group for their CF peers [61]. These
studies stress the impact of influenza on hospitalisation and
pulmonary exacerbations in young children in general, so
that vaccination is strongly encouraged from the age of 6
months. Annual vaccination is considered the best means of
protection against influenza infection. Vaccination is now
strongly recommended annually for anyone aged 6
months who, because of age or medical condition, has a
higher risk of complications of influenza [62]. The
immunisation of their family members is also recommended
[62,63]. The indications particularly include (but are not
limited to) patients with chronic diseases affecting the
respiratory tract, cardiovascular disorders, asthma, meta-
bolic diseases (diabetes mellitus), sickle cell disease, HIV,
renal dysfunction and their household members [62–65].
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benefit from influenza vaccination, not merely the adult
population [2,66]. However, because vaccines are currently
not approved for children <6 months of age, and the
majority are poorly immunogenic in young children in
general, vaccination is often postponed. Children aged 6–35
months need 2 (half) doses with a 1-month interval.
Children between 3 and 8 years who are receiving influenza
vaccine for the 1st time should receive 2 doses separated by
at least 4 weeks, but for the succeeding seasons a single
dose is sufficient in this age group as in adults. However,
note that a uniform vaccination schedule is not agreed, and
some advise 2 doses at the 1st seasonal vaccination until the
age of 12 years. The immunogenic effect of influenza
vaccines in CF children is comparable to that of healthy
individuals [67] and several studies have demonstrated the
safety of influenza vaccinations in children with CF [68].
One study has compared a virosome adjuvant vaccine with a
subunit vaccine in paediatric CF patients detailing their
strong efficacy and tolerability [69]. The coming live
attenuated intranasal vaccines will offer an alternative more
suitable for children and reduce the number of injections.
Finally, new antiviral drugs belonging to the class of
neuramidase inhibitors were developed for the treatment and
the chemoprophylaxis of influenza. However, maximum
time to treatment is mostly within 24–48 h necessitating
rapid bedside tests for identifying influenza viruses.
Paediatric experience is almost totally lacking. Studies are
needed concerning the clinical potential of these antiviral
drugs. Prevention by appropriate use of vaccines remains
the best choice [70].7. Streptococcus pneumoniae, Haemophilus influenzae,
Neisseria meningitidis
Infection with the gram-positive coccus S. pneumoniae
is the most common cause of otitis media, community-
acquired bacterial pneumonia and bacterial meningitis.
The incidence of invasive pneumococcal disease is
estimated at 100–250 cases of pneumonia, 15–25 cases
of septicaemia and 1–2.5 cases of meningitis per 100,000
persons per year. At the present time, pneumococcal
disease remains a major health problem, both with regard
to morbidity and mortality [71,72]. There is a clear
relationship between age and susceptibility to pneumo-
coccal invasive disease. The incidence of invasive disease
is high in infants up to 2 years of age, low in teenage
children and young adults, and increases in elderly. Most
clinical isolates contain an external capsule made of
repeating oligosaccharides. More than 90 serotypes of S.
pneumoniae have been identified based on antigenic
differences in these capsular polysaccharides. In patients
with CF, the prevalence of S. pneumoniae in the
respiratory tract may be underestimated, as S. pneumoniae
is difficult to isolate from sputa often heavily infectedwith other organisms. Moreover patients who are immuno-
compromised may be more susceptible to invasive disease
[72–74].
There are currently two approaches to pneumococcal
vaccination: capsular polysaccharide vaccines and polysac-
charide-protein conjugate vaccines.
Capsular polysaccharide vaccines have been available for
more than 15 years. The present 23-valent vaccines include
25 Ag purified capsular polysaccharide antigens from each
of the 23 serotypes that represent approximately 90% of all
serotypes that cause invasive pneumococcal disease. It has
been recommended by the American Academy of Pediatrics
that all CF patients who are older than 2 years, receive the
23-valent polysaccharide vaccine [72,75]. Vaccination
results in antibody formation against an average of about
three-quarters of the antigens present in the vaccine. The
immune response to polysaccharide antigens is T-lympho-
cyte independent. Therefore, vaccination with polysacchar-
ide vaccines will confer immunity only transiently.
Thereafter, revaccination must be considered to maintain
protective immunity. The optimal timing for revaccination is
not well established at the present time. In general,
revaccination is recommended every 5–7 years in otherwise
healthy patients and every 3–5 years in patients, who may
have a more rapid decline of antibody titres and who have
an increased risk for invasive disease. Vaccination with
polysaccharide vaccines does not lead to the generation of
memory cells and results only in a weak booster effect after
revaccination. At best after revaccination, immunoglobulins
G levels return to the same range of the original post-
vaccination antibodies titres [76–78]. The existing poly-
saccharide vaccines have two major drawbacks. Firstly, they
are not effective in children younger than 2 years because
the immature immune system is unable to respond to
polysaccharide antigens; similarly, they are not fully
effective in the elderly [79]. Secondly, they confer
protective immunity against invasive disease to immuno-
competent adults [80–82], but their protective efficacy
against pneumonia has not been established beyond doubt.
A novel generation of polysaccharide–protein conjugate
vaccines is now available. The protein component of these
vaccines triggers a T cell-dependent immune response with
production of high levels of antibodies and generation of
memory cells, even when administered during the first
months of life. Infants and non-responders to the poly-
saccharide vaccines will benefit from these new conjugate
vaccines [83]. However, until now a maximum of 9–11
serotypes could be included in these vaccines. The results of
the 7-valent vaccine show a protective efficacy mainly for
the prevention of invasive disease, but also for the
prevention of radiologically confirmed pneumonia and otitis
media [84] so that pneumococcal conjugate vaccines are
used in vaccination programs in North America and in some
European countries. The 7-valent vaccine is recommended
for all children aged 2–23 months and for certain children at
risk aged 24–59 months.
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increased risk of CF patients regarding invasive pneumo-
coccal disease. Moreover, CF patients show a wide range
of pneumococcal polysaccharide antibody levels compa-
rable to a normal immunocompetent population [72,85].
Therefore, universal indiscriminate vaccination with the
actual 23-valent polysaccharide vaccines becomes an issue
in CF patients if pre-immunisation antibody levels are
unknown. Vaccination could lead to a heightened inflam-
matory reaction and additional lung damage in those with
high antibody levels and should therefore only be
considered in CF patients without protective antibodies.
The latter is particularly true when lung transplantation is
considered as transplant recipients might be at an
increased risk of pneumococcal infection [73,74,86]. CF
lung transplant recipients may also be vaccinated after
transplantation. However, as has been observed in other
transplant recipients, their post-vaccine antibody levels
will probably be lower and decline more rapidly than in
other individuals and they will probably require revacci-
nation sooner than normal subjects to maintain protective
immunity [76].
With regard to the pneumococcal conjugate vaccines,
national recommendations should be followed [13,87].
More evidence is needed before recommending conjugate
pneumococcal vaccine to all CF infants in countries without
national implementation of the vaccine and to confirm
whether they offer a better alternative for CF lung transplant
recipients as compared to the classic 23-valent vaccines.
H. influenzae is part of the normal colonising flora of
the upper respiratory tract. Most H. influenzae strains are
not encapsulated, 6 strains (a–f), however, do have a
capsule, H. influenzae type b being the most virulent
strain, responsible for invasive disease, bacterial menin-
gitis, pneumonia, otitis media, epiglottitis, cellulitis and
osteo-arthritis in children under the age of 5 years and
especially under 18 months. The capsule contains a
specific polysaccharide called polyribosyl ribitol phos-
phate (PRP). Antibodies against PRP confer protective
immunity. Most of the population is colonised by some
non-encapsulated strain of H. influenzae, including the
strains recovered often in sputa and naospharyngeal swabs
of CF patients. Only 1–5% of non-immunised persons
are colonised by H. influenzae type b, mostly young
children.
H. influenzae polysaccharide-protein conjugate vaccines
were introduced in the early nineties and are actually part of
the general vaccination recommendations for infants and
children, including CF patients. Since the start of a mass
vaccination programme in Finland invasive H. influenzae
type b infection decreased successfully [88]. Vaccination
however did not influence the presence of non-encapsulated
or non-b strains in the respiratory tract of non-CF children
[89]. Moreover rare cases of invasive capsulated H.
influenzae type b infection were recently reported in
children who failed to mount a good antibody response toimmunisation and assay of anticapsular antibody is required
if immune status is in doubt; the rare possibility of vaccine
failure should not be forgotten [90,91]. Data on vaccine
failure in general however, are scarce in CF.
Finally vaccination against serogroup C N. meningitidis
will be applicable to CF patients as for non CF subjects in
regions with increased prevalence [13,92].8. Respiratory syncytial virus
Respiratory syncytial virus (RSV) is the most important
cause of viral lower respiratory tract infection (LRTI) in
infants and children worldwide [93,94]. RSV consists of
two major antigenic groups, A and B strains, the A strains
being found predominantly in the community [93,95]. In the
United States, the risk of primary infection in infants
younger than 12 months of age ranges from 50% to 70%,
and although not all infected infants will acquire LRTI, the
latter will nevertheless reach 30–40% of the total infant
population. By the time infants reach 2 years of age, nearly
all have had a primary RSV infection and the risk of LRTI
remains high with reinfection due to lack of persistent
immunity [95]. Infants who are premature or have chronic
lung disease or congenital heart disease are at particular risk
for severe RSV disease. RSV infection can also have long-
term consequences. Approximately 50% of infants with
RSV LRTI will have recurrent episodes of wheezing during
early childhood [93,96]. After RSV bronchiolitis in infancy
an excess of respiratory symptoms for at least 10 years has
been reported [97]. Although traditionally regarded as a
paediatric pathogen, RSV can also cause life-threatening
pulmonary disease in adults with chronic obstructive
pulmonary disease or congestive heart failure [93,98],
bone-marrow transplant recipients and the elderly [93,94].
In CF adults and children, acute pulmonary exacerba-
tions and acute worsening of airway obstruction may result
from viral infection [56,99,100]. As with influenza, limited
recent studies are available. Data support the hypothesis that
RSV infection in CF, although self-limited, is accompanied
by airway inflammatory changes and plays a role in the
initial infection of the airway with P. aeruginosa
[56,57,101–104].
Data demonstrate that infants with CF and normal
controls have the same number of RSV respiratory illnesses
over a single season. However, RSV infection in CF infants
may cause significant pulmonary morbidity, a prolonged
hospitalisation and complications such as mechanical
ventilation, persistent hypoxemia and decreased lung
function for several months after LRTI [56,105]. Some
authors advice long-term prophylaxis with inhaled anti-
biotics in infants with risk situations such as RSV infection
[104]. Most authors conclude that children with CF should
be considered prime candidates for RSV prevention trials
using RSV intravenous immunoglobulin, RSV monoclonal
antibodies, and RSV subunit vaccines. However, the relative
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RSV immunity in protection and pathogenesis are still
debated, resulting in difficulties of developing an effective
vaccine [93].
Passive immunoprophylaxis with specific hyperimmune
immunoglobulin (RSVIG) [106] or humanised monoclonal
antibody (palivizumab) [107] is restricted at present to a
small number of high risk infants, such as those born at less
than 35 weeks gestation and children with bronchopulmo-
nary dysplasia. The humanised monoclonal antibody has to
be administered in a dose of 15 mg/kg body weight, once a
month during the RSV season (from September to May,
maximum 5 injections/season). No data on the effect of
palivizumab on the morbidity of CF children are available.
Clinical trials on the safety and tolerance of palivizumab in
CF patients <2 years are in progress.
Although the importance of RSV as a respiratory
pathogen has been recognised for over 30 years, a vaccine
is not yet available because of several problems inherent to
RSV vaccine development. As serious RSV disease can
occur in high-risk individuals who have experienced
previous RSV infection, as well as in RSV naı¨ve infants,
it is also likely that more than one type of RSV vaccine will
be needed for immunising all those in whom protection is
mandatory [94].
The first vaccine, a formalin-inactivated alum-precipi-
tated (FI-RSV) preparation given intramuscularly did not
protect infants and children from infection in the early
1960s. Moreover, the illness in the vaccinated group
following subsequent infection was unusually severe, with
some deaths and a high rate of hospitalisation [108].
Several strategies for the development of a live attenuated
RSV vaccine were explored. In recent years new vaccine
candidates derived by chemical mutagenesis of an
incompletely attenuated cold-passaged RSV mutant have
generated a promising vaccine candidate for seronegative
infants [109]. Naked DNA and RNA vaccines show also
considerable results. Finally subunit RSV F and G (this
glycoprotein predominantly distinguishes A and B strains)
vaccines, containing the viral glycoproteins, which induce
neutralizing and protective antibodies, have been eval-
uated as potential vaccines. A variety of vaccine strategies
are being evaluated that target different groups: these
include immunisation of breast-feeding women with the
hope of protecting neonates from RSV infection during
the critical few months of life [110], immunisation of
neonates and infants, and immunisation of high risk
groups [95].
Studies have shown that RSV infection in CF infants, as
well as in older patients can lead to a higher morbidity and
hospitalisation rate. Therefore RSV vaccination of CF
patients seems reasonable, as soon as an RSV vaccine is
available on the market. However, more studies are needed
to clarify the role of RSV infection in the morbidity of
children and adults with CF (with or without chronic P.
aeruginosa infection) and in their pulmonary exacerbations.9. Pseudomonas aeruginosa
P. aeruginosa is an opportunistic gram-negative bacterial
pathogen that produces various immunomodulatory prod-
ucts that enable it to survive in the lung and to cause
significant morbidity and mortality. Particularly at risk are
patients with compromised respiratory function, such as
burn patients and those with CF [111]. The development of
a P. aeruginosa mucoid phenotype and subsequent chronic
pulmonary infection is directly associated with the deteri-
oration of lung function in patients with CF. This chronic
infection produces an immunologically conditioned destruc-
tion of the pulmonary tissue, and can lead to fatal
bronchiectasis. The general deterioration in lung function
has a direct bearing on the quality of life of patients with CF.
Limited exercise capacity, frequent hospital admissions for
treatment of acute pulmonary exacerbation, and an associ-
ation with lowered life expectancy are all associated with a
deterioration of lung function. Its preservation should
therefore be one of the main goals in the management of
these patients. Once chronic infection of the airways by P.
aeruginosa has become established, it is virtually impos-
sible to eradicate the organism in the lower respiratory tract.
This is despite considerable progress in antibiotic treat-
ments. In addition, innate and increasing resistance of P.
aeruginosa to antibiotic therapy emphasises the need for
effective prophylaxis against P. aeruginosa infection
through active vaccination.
P. aeruginosa is occasionally detected in throat swabs of
CF patients in infancy, but there is generally a period of
several years when prophylactic measures, which poten-
tially would include vaccination, may delay or even prevent
infection [112]. This window of opportunity provides a
reasonable time frame for the vaccination of CF patients at a
very early age, which may prevent P. aeruginosa infection
in the lower respiratory tract, leading to an improved
prognosis.
There have been many approaches in the development of
vaccines for the prevention of P. aeruginosa infection but
earlier trials produced disappointing results [113]. Despite
several attempts at prophylactic vaccine development, a
recent publication investigating the effectiveness of vacci-
nation against P. aeruginosa in patients with CF revealed
that there was very little information available concerning
multi-centred, randomised controlled trials that are
adequately-powered to evaluate potential P. aeruginosa
vaccines [114]. A more recent publication has shown that
regular vaccination for a period of 10 years with a
polyvalent conjugate vaccine, reduced the incidence of
chronic infection with P. aeruginosa and was associated
with better preservation of lung function, particularly in
older patients [16]. Prospective, randomised, multicenter,
double blind, controlled trials are currently being conducted
in order to confirm the preliminary data already gathered.
Although P. aeruginosa infection alone is not sufficient
to serve as a prognostic criterion for life expectancy in CF
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is fundamental in the preservation of the patients’ quality of
life. Effective prophylaxis by immunisation against P.
aeruginosa infection in CF patients, complementing current
antibiotic therapies, remains an Funmet medical need_.10. Conclusions and future considerations
The recommendations embodied in this paper are
intended to serve as a call for special attention to achieve
correct immunisation and antiviral strategies in CF children,
adolescents and adults. They focus on the importance of
linking correct immunisation to the general care of CF
patients, who experience multiple barriers to vaccine
administration, such as cough and wheezing, school
absenteeism, hospital admissions and their complicated
multidisciplinary care. Therefore the general practitioner
or paediatrician plays an important role in coordinating this
aspect of management. This paper also calls for the
diagnosis and reporting of the effect of vaccine-preventable
diseases in CF patients at any age. In the future, new coming
antiviral vaccines will certainly be interesting for CF
patients such as Respiratory Syncytial Virus or Cytomega-
lovirus vaccines. There is also hope that antibacterial
vaccines against Pseudomonas might prevent fatal pulmo-
nary infection.References
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